Ferrocifen type anti cancer drugs.

Area of Science:

• Medicinal chemistry
• Organometallic chemistry
• Cancer biology

Background:

• Small molecules and peptides remain crucial therapeutics, with a high percentage of newly approved drugs belonging to the small molecule category.
• Medicinal organometallic chemistry offers novel therapeutic agents, such as ferroquine for malaria and bioferrocene derivatives for antiproliferative applications.
• Ferrocene's properties include stability, low toxicity, low cost, and reversible redox activity, making it attractive for drug development.

Purpose of the Study:

• To explore the diverse antitumoral approaches of ferrocifen derivatives, which are modified from tamoxifen.
• To rationalize the behavior of ferrocifen derivatives with various anticancer targets.
• To investigate the mechanistic diversity and target interactions of these compounds in cancer therapy.

Main Methods:

• Investigated ferrocifen derivatives, originally derived from tamoxifen.
• Analyzed the structural and mechanistic diversity of these compounds.
• Examined their action via various identified and unidentified targets.
• Studied concentration-dependent effects and cancer cell-specific functionalities.
• Explored mechanistic pathways including senescence and apoptosis induction.

Main Results:

• Ferrocifen derivatives exhibit remarkable structural and mechanistic diversity in their antitumoral effects.
• These compounds act on multiple targets, with effects varying based on concentration and cancer cell type.
• Mechanisms include synergistic or sequential pathways, influencing senescence and apoptosis.
• Initial successes and ferrocene's favorable properties support their development.

Conclusions:

• Ferrocifen derivatives represent a promising class of small molecule anticancer agents with multifaceted mechanisms of action.
• Understanding their diverse target interactions and pathway modulation is key to optimizing cancer therapy.
• This work provides a foundational rationalization for the behavior of these organometallic compounds against various cancer types.